

# Elena Samoilova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7849378/publications.pdf>

Version: 2024-02-01

15  
papers

131  
citations

1163117

8  
h-index

1281871

11  
g-index

15  
all docs

15  
docs citations

15  
times ranked

185  
citing authors

#	ARTICLE	IF	CITATIONS
1	Flux-gate magnetic field sensor based on yttrium iron garnet films for magnetocardiography investigations. <i>Technical Physics Letters</i> , 2016, 42, 860-864.	0.7	26
2	Compounds of IL-6 Receptor Complex during Acute Lung Injury. <i>Bulletin of Experimental Biology and Medicine</i> , 2018, 164, 609-611.	0.8	19
3	Soluble glycoprotein 130 is inversely related to severity of coronary atherosclerosis. <i>Biomarkers</i> , 2018, 23, 527-532.	1.9	15
4	Oxidized phosphatidylcholine stimulates activity of secretory phospholipase A2 group IIA and abolishes sphingomyelin-induced inhibition of the enzyme. <i>Prostaglandins and Other Lipid Mediators</i> , 2010, 91, 38-41.	1.9	11
5	The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL. <i>Molecular and Cellular Biochemistry</i> , 2005, 270, 107-113.	3.1	10
6	Halogenated phospholipids regulate secretory phospholipase A2 group IIA activity. <i>Chemistry and Physics of Lipids</i> , 2013, 167-168, 51-56.	3.2	9
7	Secretory phospholipase A2 activity in blood serum: The challenge to sense. <i>Biochemical and Biophysical Research Communications</i> , 2014, 454, 178-182.	2.1	9
8	The association of PLA2G2A single nucleotide polymorphisms with type IIA secretory phospholipase A2 level but not its activity in patients with stable coronary heart disease. <i>Gene</i> , 2015, 564, 29-34.	2.2	9
9	Opposite effects of native and oxidized lipoproteins on the activity of secretory phospholipase A2 group IIA. <i>Prostaglandins and Other Lipid Mediators</i> , 2009, 90, 37-41.	1.9	8
10	Pro-inflammatory cytokines in chronic cardiac failure: state of problem. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1389-1394.	0.8	7
11	Effects of LDL Lipids on Activity of Group IIA Secretory Phospholipase A2. <i>Bulletin of Experimental Biology and Medicine</i> , 2010, 150, 39-41.	0.8	4
12	Decision rule for stratification of patients with chronic heart failure of functional class II and III. <i>Bulletin of Siberian Medicine</i> , 2020, 19, 101-107.	0.3	2
13	Inhibition of Meprins Reduces Pulmonary Edema in LPS-Induced Acute Lung Damage. <i>Bulletin of Experimental Biology and Medicine</i> , 2019, 166, 719-721.	0.8	1
14	Diagnostic prediction models of stratifying chronic heart failure patients based on the underlying disease. <i>Complex Issues of Cardiovascular Diseases</i> , 2021, 10, 6-15.	0.5	1
15	Effect of serum from cardiovascular patients on catalytic activity of secretory phospholipase A2 (IIA). <i>Bulletin of Experimental Biology and Medicine</i> , 2006, 142, 581-582.	0.8	0